bioAffinity Technologies
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, bioAffinity Technologies sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
bioAffinity Technologies: 4 sponsored US clinical trials, 2 recruiting.
bioAffinity Technologies sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. The most-studied condition in this pipeline is Lung Cancer (Diagnosis), with 1 trials.
Upper-quartile sponsor footprint
bioAffinity Technologies sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
NCT07168993
Collection of Sputum and Labeling for Lung Cancer
NCT03457415
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
NCT03837600
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
NCT02388074
Therapeutic Areas
What is open in the bioAffinity Technologies pipeline
2 recruiting of 4 indexed (50% open); 2 completed (50%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Lung Cancer (Diagnosis) (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
bioAffinity Technologies: open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
bioAffinity Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this bioAffinity Technologies page
4 registered trials is a research-attention snapshot, not an endorsement of bioAffinity Technologies or any single study.
- 2 of bioAffinity Technologies's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lung Cancer (Diagnosis) is the condition bioAffinity Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lung Cancer (Diagnosis) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
bioAffinity Technologies pipeline card: 4 registered trials from official public datasets.Report a data error.